Ireland
--:--IST
Latest
Clinical Trials in Sweden / NCT05329285
Recruiting Not applicable

CABG or PCI in Patients With Ischemic Cardiomyopathy

NCT05329285 · tracked via the Priya Life Science Sweden tracker
Phase
Not applicable
Started
2022-09-14
Last updated
2024-06-24

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

Percutaneous Coronary Intervention (PCI)

Percutaneous Coronary Intervention (PCI): Alternative treatment

Study summary

The STICH-SWEDEHEART trial will compare PCI vs CABG for revascularization of patients with HF and LV systolic dysfunction (LV ejection fraction (LVEF) \<40%) and multi-vessel coronary artery disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥18 years. 2. Symptomatic HF defined as NYHA HF class II-IV within 1 month of enrolment 3. LVEF ≤ 40% quantified by either echocardiography or gated SPECT ventriculography, or magnetic resonance (MR) or any other recognized assessment of LVEF 4. Meaningful amount of myocardium at risk because of CAD (BCIS myocardial jeopardy score ≥ 6 on a recent (\> 6 months) coronary angiogram); 5. Heart team believes that a meaningful revascularization can be achieved by both PCI or CABG, with complete revascularization defined as residual ischemia in \<10% of the left ventricle 6. Heart team agrees that guideline directed medical therapy (GDMT) has been initiated for ≥1 month in prevalent and newly diagnosed cases. In patients hospitalized with newly diagnosed iLVSD (with or without acute coronary syndrome (ACS)) requiring revascularization before discharge, GDMT needs to be initiated, when possible, in-hospital before randomization, with the expectation that it will be titrated to maximally tolerated doses after revascularization 7. Written informed consent obtained Exclusion Criteria: 1. Previous randomization in the study 2. Decompensated heart failure requiring inotropic /adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ventricular assist device therapy less than 48 hours prior to randomization 3. Recent (\<1 month) type 1 myocardial infarction 4. Recent PCI (\<3 months) 5. Valvular heart disease or any other cardiac conditions (e.g. LV aneurysm) requiring surgical repair/replacement 6. Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy 7. Expected survival less than 3 years due to non-cardiac illness 8. Circumstances likely to lead to poor treatment compliance 9. Individuals for whom record in public health databases is not accessible (non-eligibility to public health system, parallel healthcare systems 10. Pregnancy or woman of childbearing potential who is not sterilized or using a medically accepted form of contraception

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Kardiologen Gothenburg Sweden Recruiting

More Vastra Gotaland Region trials in Sweden

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05329285 on ClinicalTrials.gov ↗ ← All trials in Sweden